ATH686

Item no.	HY-15003-10mg
Manufacturer	MedChem Express
CASRN	853299-52-2
Amount	10 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Molecules
Specific against	other
Purity	99.38
Formula	C25H28F3N7O2
Citations	[1]Ellen Weisberg, et al. Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison. Genes Cancer. 2010 Oct;1(10):1021-32.
Smiles	NC1=NC(OC2=CC=C(NC(NC3=CC(C(F)(F)F)=C(CN4CCN(CC)CC4)C=C3)=O)C=C2)=CC=N1
ECLASS 5.1	32169090
ECLASS 6.1	32169090
ECLASS 8.0	32169090
ECLASS 9.0	32169090
ECLASS 10.0.1	32169090
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Available
Product Description	ATH686 is a potent, selective and ATP-competitive FLT3 inhibitor. ATH686 target mutant FLT3 protein kinase activity and inhibit the proliferation of cells harboring FLT3 mutants via induction of apoptosis and cell cycle inhibition. ATH686 has antileukemic effects[1].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	515.53
Clinical_Information	No Development Reported
Manufacturers Research_Area	Cancer
Solubility	DMSO : 250 mg/mL (ultrasonic)
Pathway	Apoptosis; Protein Tyrosine Kinase/RTK
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 10 mg

available

Request delivery time